BPC-157

BPC-157, short for Body Protection Compound-157, is a synthetic pentadecapeptide — a 15-amino-acid sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from a partial fragment of a gastric-juice protein first identified for its tissue-protective properties in rat gastric mucosa. Unlike single-target peptides that mimic a single endogenous hormone, BPC-157 is studied for pleiotropic effects across several repair and signaling pathways simultaneously.

Its best-characterized mechanism is potent up-regulation of the VEGFR2 (vascular endothelial growth factor receptor 2) pathway. Activation of this receptor drives angiogenesis — the formation of new capillary networks — which researchers associate with accelerated recovery in tendon, ligament, muscle, and gastrointestinal mucosal injury models. Animal studies also demonstrate that BPC-157 upregulates focal adhesion kinase (FAK) and paxillin, cytoskeletal scaffolding proteins that coordinate fibroblast migration, cell-matrix adhesion, and connective tissue remodeling during wound repair. This FAK/paxillin axis is distinct from pure angiogenic signaling and may account for BPC-157's reported effects on fibroblast proliferation and extracellular matrix deposition in tendon lesion models.

A second major mechanistic axis is modulation of nitric oxide (NO) signaling, a pathway implicated in vascular tone, gut motility, and cytoprotection during ischemia-reperfusion injury. BPC-157 appears to both up-regulate endogenous nitric oxide synthase (eNOS) expression and buffer the excessive NO production that contributes to organ damage during reperfusion, which may underlie its protective effects in hepatic, colonic, and renal ischemia models.

Beyond the VEGFR2 and NO axes, early-phase research documents interaction with the dopaminergic and serotonergic systems. Rodent studies show that BPC-157 modulates mesolimbic dopamine release and attenuates the behavioral consequences of dopamine-blocking agents, leading researchers to study it in models of movement disorders and drug-induced extrapyramidal symptoms. Serotonin receptor modulation has been documented alongside observations of anti-depressant-like behavioral effects in forced-swim and tail-suspension rodent assays.

The compound's apparent stability across a wide pH range and resistance to enzymatic degradation — characteristics unusual for most research peptides — make it a distinctive subject for oral-route peptide research. Most research peptides are limited to injectable or topical study designs due to rapid gastrointestinal proteolysis; BPC-157's resistance to pepsin and other gut proteases has driven a distinct body of oral-route mechanistic work, including models of inflammatory bowel disease, gastric ulcer healing, and short-bowel syndrome that specifically exploit the oral route's clinical translatability. Peptides.SO currently tracks 242 supplier listings for BPC-157 from 94 distinct vendors, all currently marked in stock. Across the 224 listings whose quantities normalize to a per-milligram basis the median price is $55.00/mg, with the lowest verified per-mg price at $0.24/mg (Buy Peptides USA at $36.99 for ~154 mg) and the interquartile range spanning $8.40 to $114.95/mg — one of the widest price spreads in the market, largely driven by vial-size differences.

Potential Research Applications: Tendon, ligament, and muscle injury repair models involving VEGFR2 up-regulation and angiogenesis Gastric and intestinal mucosal ulcer healing via oral or systemic routes FAK/paxillin-mediated fibroblast migration and connective tissue remodeling studies Ischemia-reperfusion injury and cytoprotection research in hepatic, renal, and colonic models Nitric oxide signaling and eNOS modulation in vascular tone and gut motility research Post-surgical soft tissue and connective tissue recovery in rodent surgical-section models Dopaminergic system modulation and extrapyramidal symptom attenuation models Serotonin receptor interaction and antidepressant-like behavioral assays Inflammatory bowel disease and short-bowel syndrome in oral-route study designs Bone and periodontal healing research models

Marketplace Snapshot (September 2026, Peptides.SO listings data): Tracked listings: 242 from 94 distinct suppliers (242 in stock) Unit breakdown: 224 per-mg listings, 10 per-mcg listings, 5 per-capsule listings Median price (mg-unit listings): $55.00/mg (interquartile range $8.40 – $114.95/mg) Lowest verified per-mg price: $0.24/mg — Buy Peptides USA ($36.99 for ~154 mg) Second lowest: $0.32/mg — Almighty Peptides ($159 for ~497 mg) Third lowest: $0.36/mg — HK Peptides Worldwide ($56 for ~156 mg) Note: The extreme price dispersion for BPC-157 (from $0.24 to $619/unit) is larger than for almost any other peptide on this platform, and is almost entirely driven by vial-size differences and bundling rather than by actual per-mg cost. Researchers should always compute cost per milligram from the quantity and total price before comparing listings.

Frequently Asked Questions: Q: How many suppliers list BPC-157 on Peptides.SO, and what does it typically cost per milligram? A: Peptides.SO tracks 242 BPC-157 listings from 94 distinct vendors, all currently in stock. Among the 224 listings with mg-denominated pricing, the median works out to $55.00/mg with a wide interquartile range from $8.40 to $114.95/mg. The low end of the market (around $0.24–$0.40/mg) reflects high-volume or multi-vial packs from suppliers like Buy Peptides USA, Almighty Peptides, and HK Peptides Worldwide.

Q: What makes BPC-157 unusual compared with other research peptides? A: Two properties set it apart. First, its primary mechanism — VEGFR2 up-regulation and angiogenesis — operates through a defined receptor pathway rather than through simple mimicry of an endogenous hormone, giving researchers a more tractable mechanistic target. Second, it is unusually stable in the gastric environment, resisting pepsin and acid degradation in ways that most synthetic peptides do not, which makes it one of the very few research peptides studied in oral-route in vivo models.

Q: How does BPC-157 differ from TB-500 (Thymosin Beta-4)? A: BPC-157 and TB-500 are both studied in tissue-repair contexts but operate through distinct mechanisms. BPC-157 acts primarily via the VEGFR2/FAK/paxillin axis and NO signaling with documented gastric-mucosal and CNS-modulatory effects. TB-500 acts primarily by binding G-actin and sequestering it from F-actin polymerization, modulating cell migration and inflammation through a cytoskeletal mechanism. Some researchers study them in combination to achieve complementary tissue-repair effects, though no direct comparative human data exist.

Q: What documentation should researchers request before purchasing BPC-157? A: A batch-specific certificate of analysis reporting both HPLC purity (ideally ≥98%) and mass-spectrometry identity confirmation, with the molecular weight match to 1419.55 Da (the MW of BPC-157 free base). Generic or undated COAs without lot traceability, and COAs reporting only purity without confirming molecular identity, provide substantially weaker assurance. With 94 suppliers tracked, the platform's COA and testing-score data can help researchers compare documentation standards across vendors.

Q: What is the significance of BPC-157's effect on the FAK/paxillin pathway? A: Focal adhesion kinase (FAK) and paxillin are scaffolding proteins at the junction between the extracellular matrix and the cytoskeleton. Their activation promotes fibroblast spreading, directed cell migration into wound sites, and deposition of collagen and other extracellular matrix components. BPC-157's up-regulation of FAK and paxillin in tendon fibroblast culture studies suggests it may accelerate the cellular infiltration phase of connective tissue repair, complementing its VEGFR2-driven vascular effects.

Q: Is BPC-157 approved for human use? A: No. BPC-157 is an unapproved research chemical with no FDA approval or IND status for any clinical indication. All material listed on this platform is sold strictly for in vitro and preclinical laboratory investigation. It is not a drug, is not approved for human or veterinary consumption, and may not be used in clinical practice.

Related Research on Peptides.SO: peptides.so/learn/bpc-157-complete-guide peptides.so/learn/bpc-157-vs-tb-500-regenerative-peptides-compared peptides.so/peptide/bpc-157-tb-500 peptides.so/learn/peptide-purity-testing-hplc-mass-spec peptides.so/learn/how-to-reconstitute-peptides peptides.so/tools/calculator

Cited Research: Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333. PubMed PMID: 27847966. Sikiric P, Rucman R, Turkovic B, et al. Novel Cytoprotective Mediator, Stable Gastric Pentadecapeptide BPC 157. Vascular Recruitment and Gastrointestinal Tract Healing. Curr Pharm Des. 2018;24(18):1990-2001. PubMed PMID: 29769003. Vasireddi N, Singh V, Lall RP, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025. PubMed PMID: 40756949.

For laboratory research only. Not for human or veterinary use, diagnosis, treatment, cure, or prevention of any disease. THIS PRODUCT IS NOT FOR HUMAN CONSUMPTION.